NEW YORK ─ Magnolia Medical Technologies said on Friday that a jury in the US District Court of Delaware has ruled in its favor in a lawsuit involving Kurin, a San Diego-based competitor in the blood culture collection device market.
The jury unanimously ruled that Kurin has been using Magnolia Medical's Initial Specimen Diversion Device technology without the latter's permission, and reaffirmed Magnolia Medical's ownership of the technology. According to court documents, the jury awarded Magnolia Medical $2.1 million in damages.
On deadline, Kurin had not responded to a request for comment.
CEO and Cofounder Greg Bullington said in a statement that the verdicts in the case reflect "extensive evidence presented across two phases of the trial," and affirm the value of its technology and market position. He added that the rulings will support its strategy to "establish a new standard of care for sepsis testing accuracy" based around its Steripath blood culture collection system.
Magnolia Medical and Kurin have been involved in multiple legal disputes for years. In 2020, the US District Court for the Southern District of California ruled in Magnolia Medical's favor in a false advertising lawsuit brought by Kurin in 2018. That same year, Magnolia countersued Kurin, and in 2019 updated its suit to allege that Kurin's Kurin Lock device, a blood collection system, infringed its IP.